Horizon Pharma, which is launching DUEXIS for pain relief in rheumatoid arthritis/osteoarthritis patients, will see its quiet period end on Tuesday, September 6. On July 27, the company raised $50 million by offering 5.5 million shares at $9, below the range of $10 to $12. Stifel Nicolaus Weisel, Cowen & Company and JMP Securities acted as lead managers on the deal.
